Quarterly report pursuant to Section 13 or 15(d)

Acquisitions (Details Textual)

v3.4.0.3
Acquisitions (Details Textual) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Mar. 07, 2016
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total $ (2,442,433) $ (2,801,086)  
Jade Therapeutics, Inc [Member]      
Business Acquisition, Percentage of Voting Interests Acquired     100.00%
Business Combination, Consideration Transferred, Liabilities Incurred $ 300,000    
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 765,728    
Percentage Of Common Stock Issued 90.00%    
Percentage Of Common Stock To Be Issued 10.00%    
Business Combination, Contingent Consideration, Liability $ 2,164,451    
Stock Issued During Period, Value, New Issues $ 2,910,000    
Business Acquisition, Share Price $ 3.80    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $ 186,000    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets 369,000    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total $ (118,000)    
Finite-Lived Intangible Asset, Useful Life 3 years    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables $ 46,000    
Jade Therapeutics, Inc [Member] | Selling, General and Administrative Expenses [Member]      
Business Combination, Acquisition Related Costs $ 234,000